Form 4: Recursion Pharmaceuticals Executive Tina Marriott Reports Stock Transaction
SEC Form 4 Filing
Tina Marriott, President and COO of Recursion Pharmaceuticals, sold 14,286 shares of Class A Common Stock to cover tax obligations related to restricted stock units.
Summary
- Tina Marriott, President and COO of Recursion Pharmaceuticals, filed a Form 4 disclosing a transaction involving the company's stock.
- On November 15, 2024, Ms. Marriott disposed of 14,286 shares of Class A Common Stock at a price of $6.175 per share.
- This transaction was to cover tax withholding obligations related to the net settlement of restricted stock units.
- Following the transaction, Ms. Marriott directly owns 506,852 shares of Class A Common Stock.
- The filing also details Ms. Marriott's holdings of various stock options with different exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing of a stock transaction, which is neither positive nor negative for the company's outlook.
Industry Context
This is a routine filing for an executive stock transaction and is common practice for publicly traded companies.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
- The transaction is a common occurrence where executives sell shares to cover tax obligations related to stock-based compensation.
- The vesting schedules of the stock options are typical for executive compensation packages in the biotech industry.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale of shares by an executive.
- The sale does not indicate any change in the company's fundamentals or outlook.
Key Dates
| Date | Description |
|---|---|
| 02/04/2022 | Date of a stock option grant with an exercise price of $11.4. |
| 03/01/2022 | Vesting start date for a stock option with an exercise price of $11.4. |
| 03/01/2023 | Vesting start date for a stock option with an exercise price of $8.55. |
| 03/01/2024 | Vesting start date for a stock option with an exercise price of $10.09. |
| 11/15/2024 | Date of the reported stock sale transaction. |
| 11/19/2024 | Date the Form 4 was signed. |
Keywords
Form 4, insider trading, stock transaction, Recursion Pharmaceuticals, Tina Marriott, Class A Common Stock, stock options, restricted stock units, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.